Ranbaxy gets FDA nod for migrane drug

India's largest pharmaceutical company Ranbaxy Laboratories, has received a tentative approval from the US Food and Drug Administration (US FDA) to manufacture and market sumatriptan succinate tablets, for the treatment of acute migraine attacks in adults, in US. The market share for sumatriptan in the US is pegged at $857 million annually.

Jim Meehan, vice-president (sales and marketing), Ranbaxy Pharmaceuticals Inc-the US subsidiary of Ranbaxy Labs-said that "This product""to be launched after a final US FDA approval""holds immense potential for Ranbaxy as it will expand our growing portfolio of affordable generic product formulations."